EGRX - Eagle Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
21.39
+0.69 (+3.33%)
As of 03:26PM EDT. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close20.70
Open20.83
Bid21.32 x 1000
Ask21.35 x 1100
Day's Range20.83 - 21.39
52 Week Range18.89 - 48.60
Volume91,085
Avg. Volume164,917
Market Cap280.023M
Beta (5Y Monthly)0.91
PE Ratio (TTM)N/A
EPS (TTM)-0.27
Earnings DateAug 07, 2023 - Aug 11, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
13% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for EGRX

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Eagle Pharmaceuticals Announces Acceptance of Two Abstracts at the Society for Academic Emergency Medicine (SAEM) Annual Meeting

    Abstracts to be presented cover preclinical data on RYANODEX® (dantrolene sodium) for injectable suspension in Acute Radiation Syndrome and Traumatic Brain InjuryWOODCLIFF LAKE, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that two abstracts were accepted for presentation at the Society for Academic Emergency Medicine (SAEM) Annual Meeting, being held May 16-19, 2023, in Austin, Texas. “We are pleased to have the opp

  • Zacks

    Eagle Pharmaceuticals (EGRX) Q1 Earnings and Revenues Beat Estimates

    Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 5.88% and 3.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Eagle Pharmaceuticals Reports First Quarter 2023 Results

    Total revenue for Q1 2023 was $66.3 million, compared to $115.9 million in Q1 2022Q1 2023 net income was $0.44 per basic and diluted share and adjusted non-GAAP net income1 was $1.27 per basic and $1.26 per diluted shareQ1 2023 adjusted non-GAAP EBITDA of $22.3 millionQ1 2023 net sales of PEMFEXY® totaled $22.9 million; Eagle estimates that it has an approximate 15% share in commercial (non-340B) pemetrexed market for the second quarter of 2023 to date2BENDEKA®3 and BELRAPZO®4 - both ready-to-di

  • Simply Wall St.

    Eagle Pharmaceuticals (NASDAQ:EGRX) shareholders have endured a 55% loss from investing in the stock five years ago

    We think intelligent long term investing is the way to go. But no-one is immune from buying too high. Zooming in on an...

  • GlobeNewswire

    Eagle Pharmaceuticals Granted Unique J-Code for Byfavo®¹ (remimazolam for injection) from CMS

    -- Byfavo1 is indicated for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less WOODCLIFF LAKE, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the Centers for Medicare & Medicaid Services (“CMS”) has established a unique, product-specific billing code for Byfavo®1 (remimazolam for injection), a short-acting sedative for procedures lasting 30 minutes or le

  • GlobeNewswire

    Eagle Pharmaceuticals to Host First Quarter 2023 Financial Results on May 9, 2023

    WOODCLIFF LAKE, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its first quarter 2023 financial results on Tuesday, May 9, 2023, before the market opens. Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows: Date Tuesday, May 9, 2023Time 8:30 a.m. ETToll free (U.S.) 800-274-8461Inter

  • GlobeNewswire

    Eagle Pharmaceuticals Reaches Settlement Agreement with Dr. Reddy’s Laboratories Inc. and Dr. Reddy’s Laboratories Ltd. Related to BENDEKA® (bendamustine hydrochloride)

    WOODCLIFF LAKE, N.J., April 05, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has reached a settlement agreement with Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc. (collectively, “Dr. Reddy’s”). Eagle had asserted its Orange Book-listed patents against Dr. Reddy’s related to its new drug application referencing BENDEKA®. Under the settlement agreement, Dr. Reddy’s has the right to market its product begi

  • Simply Wall St.

    Eagle Pharmaceuticals Full Year 2022 Earnings: EPS Beats Expectations, Revenues Lag

    Eagle Pharmaceuticals ( NASDAQ:EGRX ) Full Year 2022 Results Key Financial Results Revenue: US$316.6m (up 85% from FY...

  • Insider Monkey

    Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Q4 2022 Earnings Call Transcript

    Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Q4 2022 Earnings Call Transcript March 13, 2023 Operator: Good morning, everyone. My name is Todd, and I’ll be your conference operator. At this time, I’d like to welcome everyone to Eagle Pharmaceuticals Fourth Quarter and Full-Year 2022 Financial Results . All lines have been placed on mute to prevent any […]

  • Thomson Reuters StreetEvents

    Q4 2022 Eagle Pharmaceuticals Inc Earnings Call

    Q4 2022 Eagle Pharmaceuticals Inc Earnings Call

  • Zacks

    Eagle Pharmaceuticals (EGRX) Beats Q4 Earnings and Revenue Estimates

    Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 41.03% and 2.90%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results

    • Q4 2022 net income was $0.63 per basic and $0.62 per diluted share and adjusted non-GAAP net income was $1.11 per basic and $1.10 per diluted share1 • Total revenue for Q4 2022 was $60.7 million, compared to $42.3 million in Q4 2021 • FY 2022 net income was $2.76 per basic and $2.73 per diluted share and adjusted non-GAAP net income was $7.87 per basic and $7.79 per diluted share1 • FY 2022 revenue was $316.6 million compared to $171.5 million in FY 2021 • FY 2022 net sales of PEMFEXY® totaled

  • GlobeNewswire

    Eagle Pharmaceuticals to Present at the Barclays Global Healthcare Conference

    WOODCLIFF LAKE, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will participate in a fireside chat at the Barclays Global Healthcare Conference, in Miami, FL, as follows: Date:Wednesday, March 15, 2023 Time:2:35pm ETWebcast:Click Here To schedule a 1x1 meeting, please contact your Barclays representative. About Eagle Pharmaceutica

  • GlobeNewswire

    Eagle Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023

    WOODCLIFF LAKE, N.J., March 03, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its fourth quarter and full year 2022 financial results on Monday, March 13, 2023, before the market opens.Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows: Date: Monday, March 13, 2023 Time: 8:30 a.m. ET Toll free (U

  • GlobeNewswire

    Eagle Pharmaceuticals Provides Business Update and Guidance for 2023

    WOODCLIFF LAKE, N.J., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided a business update and guidance for 2023. Highlights: During the 12 months ended September 30, 2022, Eagle recorded net income of $21.3 million or $1.63 per diluted share and adjusted EBITDA of $125.6 million and non-GAAP earnings per diluted share of $7.54, a significant increase from 2021.1Eagle exited 2022 with an approximate 6%2 share of the commercial s

  • Insider Monkey

    What Made Eagle Pharmaceuticals (EGRX) Stock to Decline in Q3?

    Scout Investments, an affiliate of Carillon Tower Advisers, an investment management company, released its “Carillon Scout Small Cap Fund” third quarter 2022 investor letter. You can download a copy of the same here. The fund underperformed in the quarter relative to its Russell 2000 Growth Index benchmark. Macroeconomic headwinds affected the performance of the fund in the […]

  • Zacks

    Should Value Investors Buy Eagle Pharmaceuticals (EGRX) Stock?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • GlobeNewswire

    Eagle Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

    WOODCLIFF LAKE, N.J., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference as follows: Date:Tuesday, January 10, 2023Time:10:30AM PT/1:30PM ETWebcast:Click Here The webcast of the presentation will be accessible for 30 days thereafter, via the Company’s website at www.eagleus.co

  • GlobeNewswire

    Eagle Pharmaceuticals Receives FDA Approval for Additional Indication for PEMFEXY® in Combination with Pembrolizumab and Platinum Chemotherapy

    -- Additional indication is for the initial treatment of patients with metastatic, non-squamous, non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations -- -- Represents the fifth indication for PEMFEXY, a ready-to-use liquid with a unique J-code approved to treat non-squamous non-small cell lung cancer and mesothelioma -- WOODCLIFF LAKE, N.J., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) announced today that the U.S. Fo

  • Zacks

    Are Investors Undervaluing Eagle Pharmaceuticals (EGRX) Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • GlobeNewswire

    Eagle Pharmaceuticals Reaches Settlement Agreement with Accord Healthcare, Inc. Related to BENDEKA® (bendamustine hydrochloride)

    WOODCLIFF LAKE, N.J., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has reached a settlement agreement with Accord Healthcare, Inc. (“Accord”). Eagle had asserted its Orange Book-listed patents against Accord related to Accord’s new drug application (“NDA”) referencing BENDEKA®. The settlement agreement provides that Accord has the right to market its product beginning January 17, 2028, or earlier based on certain

  • Simply Wall St.

    Can Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Performance Keep Up Given Its Mixed Bag Of Fundamentals?

    Eagle Pharmaceuticals' (NASDAQ:EGRX) stock is up by 8.7% over the past three months. However, the company's financials...

  • GlobeNewswire

    Eagle Pharmaceuticals’ Investor Day to Focus on Acute Care Products and Pipeline Programs; Tuesday, December 6, 2022, at 8:00am ET at the Lotte New York Palace

    KOL headshot KOL headshot KOL headshot KOL headshot KOL headshot KOL headshot -- Featured speakers and KOLs include: Scott Tarriff, Herm Cukier, Dr. Richard Dutton, Dr. Prem Fort, Dr. TJ Gan, Dr. Andre Kalil, Dr. Joseph Pergolizzi and Dr. Eugene Vortsman -- -- Topics include the clinical and scientific rationale for the Company’s hospital-based products and pipeline programs: Enalare’s ENA-001, CAL02, BARHEMSYS®, BYFAVO® and landiolol -- WOODCLIFF LAKE, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Ea

  • GlobeNewswire

    Eagle Pharmaceuticals’ Investor Day to Feature World-Renowned KOLs on Tuesday, December 6, 2022, at the Lotte New York Palace Hotel

    -- Featured speakers and KOLs include: Scott Tarriff, Herm Cukier, Dr. Richard Dutton, Dr. Prem Fort, Dr. TJ Gan, Dr. Andre Kalil, Dr. Joseph Pergolizzi and Dr. Eugene Vortsman -- -- Topics include the clinical and scientific rationale for the Company’s hospital-based products and pipeline programs: Enalare’s ENA-001, CAL02, BARHEMSYS®, BYFAVO® and landiolol -- WOODCLIFF LAKE, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today anno

  • GlobeNewswire

    Eagle Pharmaceuticals Announces FDA Acceptance of Investigational New Drug Application for CAL02, a Novel First-in-Class Broad-Spectrum Anti-Virulence Agent for the Adjunct Treatment of Severe Community-Acquired Bacterial Pneumonia

    -- Expect to begin a Phase 2 study in approximately 276 patients with severe community-acquired pneumonia at approximately 120 sites worldwide -- -- Patient enrollment expected to commence as early as the beginning of 2023 -- -- CAL02 is being developed as an adjunct to the clinically indicated antibiotic treatment -- WOODCLIFF LAKE, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) announced today that the U.S. Food and Drug Administra